2024

• Sep 27, 2024

  Jacobio Received RMB 172 million Payment

  [More]
• Sep 26, 2024

  Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE

  [More]
• Sep 20, 2024

  Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA

  [More]
• Sep 15, 2024

  Jacobio Pharma Presents Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels

  [More]
• Aug 30, 2024

  Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

  [More]
• Aug 12, 2024

  Jacobio’s SHP2 Inhibitor JAB-3312 Published in Journal of Medicinal Chemistry

  [More]
• Aug 7, 2024

  Jacobio Completes First Patient Dosage in the Phase III Clinical Trial of JAB-3312 in Combination with Glecirasib

  [More]
• Jul 26, 2024

  Jacobio Completes First Patient Dosage of p53 Y220C Activator

  [More]
• Jul 15, 2024

  Jacobio Appoints Dr. Michael Ren as Vice President of Chemistry

  [More]
• Jun 13, 2024

  Jacobio Appoints Dr. Alan Xiao as Vice President of Clinical Pharmacology

  [More]
• Jun 2, 2024

  Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

  [More]
• May 21, 2024

  Jacobio Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for Glecirasib

  [More]
• May 10, 2024

  Jacobio Announces China CDE Clearance for Phase III Clinical Trial of KRAS G12C Inhibitor Glecirasib in Patients with Colorectal Cancer

  [More]
• May 6, 2024

  Jacobio Announces the Submission of New Drug Application for Glecirasib

  [More]
• May 1, 2024

  Jacobio Pharma Announced its KRAS G12C Inhibitor Reached the Primary Endpoint

  [More]
• Apr 26, 2024

  Jacobio Pharma to Announce Two Oral Presentation at 2024 ASCO

  [More]
• Apr 17, 2024

  Jacobio Receives Orphan Drug Designations for Glecirasib for Pancreatic Cancer in the U.S.

  [More]
• Apr 9, 2024

  Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

  [More]
• Mar 28, 2024

  Jacobio Pharma Announces 2023 Annual Results

  [More]
• Mar 1, 2024

  Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30355 in the U.S.

  [More]